CPHI
Price
$1.54
Change
+$0.02 (+1.32%)
Updated
Nov 19 closing price
Capitalization
7.73M
Intraday BUY SELL Signals
CRON
Price
$2.36
Change
-$0.08 (-3.28%)
Updated
Nov 19 closing price
Capitalization
911.39M
103 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CPHI vs CRON

Header iconCPHI vs CRON Comparison
Open Charts CPHI vs CRONBanner chart's image
China Pharma Holdings
Price$1.54
Change+$0.02 (+1.32%)
Volume$6.65K
Capitalization7.73M
Cronos Group
Price$2.36
Change-$0.08 (-3.28%)
Volume$882.69K
Capitalization911.39M
CPHI vs CRON Comparison Chart in %
CPHI
Daily Signal:
Gain/Loss:
CRON
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CPHI vs. CRON commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CPHI is a Hold and CRON is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (CPHI: $1.54 vs. CRON: $2.36)
Brand notoriety: CPHI and CRON are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CPHI: 51% vs. CRON: 43%
Market capitalization -- CPHI: $7.73M vs. CRON: $911.39M
CPHI [@Pharmaceuticals: Generic] is valued at $7.73M. CRON’s [@Pharmaceuticals: Generic] market capitalization is $911.39M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CPHI’s FA Score shows that 0 FA rating(s) are green whileCRON’s FA Score has 1 green FA rating(s).

  • CPHI’s FA Score: 0 green, 5 red.
  • CRON’s FA Score: 1 green, 4 red.
According to our system of comparison, CRON is a better buy in the long-term than CPHI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CPHI’s TA Score shows that 5 TA indicator(s) are bullish while CRON’s TA Score has 3 bullish TA indicator(s).

  • CPHI’s TA Score: 5 bullish, 4 bearish.
  • CRON’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CPHI is a better buy in the short-term than CRON.

Price Growth

CPHI (@Pharmaceuticals: Generic) experienced а -1.03% price change this week, while CRON (@Pharmaceuticals: Generic) price change was -7.09% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.42%. For the same industry, the average monthly price growth was -7.04%, and the average quarterly price growth was +26.76%.

Reported Earning Dates

CRON is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-4.42% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRON($911M) has a higher market cap than CPHI($7.73M). CRON YTD gains are higher at: 16.832 vs. CPHI (-33.763). CPHI has higher annual earnings (EBITDA): -1.74M vs. CRON (-25.58M). CRON has more cash in the bank: 834M vs. CPHI (625K). CRON has less debt than CPHI: CRON (2.01M) vs CPHI (3.43M). CRON has higher revenues than CPHI: CRON (130M) vs CPHI (4.4M).
CPHICRONCPHI / CRON
Capitalization7.73M911M1%
EBITDA-1.74M-25.58M7%
Gain YTD-33.76316.832-201%
P/E RatioN/A21.45-
Revenue4.4M130M3%
Total Cash625K834M0%
Total Debt3.43M2.01M170%
FUNDAMENTALS RATINGS
CPHI vs CRON: Fundamental Ratings
CPHI
CRON
OUTLOOK RATING
1..100
7014
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9686
PRICE GROWTH RATING
1..100
6450
P/E GROWTH RATING
1..100
10024
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CPHI's Valuation (48) in the Pharmaceuticals Generic industry is in the same range as CRON (58) in the Pharmaceuticals Other industry. This means that CPHI’s stock grew similarly to CRON’s over the last 12 months.

CPHI's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as CRON (100) in the Pharmaceuticals Other industry. This means that CPHI’s stock grew similarly to CRON’s over the last 12 months.

CRON's SMR Rating (86) in the Pharmaceuticals Other industry is in the same range as CPHI (96) in the Pharmaceuticals Generic industry. This means that CRON’s stock grew similarly to CPHI’s over the last 12 months.

CRON's Price Growth Rating (50) in the Pharmaceuticals Other industry is in the same range as CPHI (64) in the Pharmaceuticals Generic industry. This means that CRON’s stock grew similarly to CPHI’s over the last 12 months.

CRON's P/E Growth Rating (24) in the Pharmaceuticals Other industry is significantly better than the same rating for CPHI (100) in the Pharmaceuticals Generic industry. This means that CRON’s stock grew significantly faster than CPHI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CPHICRON
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 11 days ago
71%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CPHI
Daily Signal:
Gain/Loss:
CRON
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EQNTX23.220.01
+0.04%
MFS Equity Income R3
BHEIX28.94N/A
N/A
BlackRock High Equity Income K
JABIX12.42N/A
N/A
JHancock Real Estate Securities R6
CVLEX15.28N/A
N/A
Cullen Value Retail
LGLOX57.11N/A
N/A
Lord Abbett Growth Leaders F3

CPHI and

Correlation & Price change

A.I.dvisor tells us that CPHI and TAK have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CPHI and TAK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPHI
1D Price
Change %
CPHI100%
+1.32%
TAK - CPHI
26%
Poorly correlated
+0.14%
ASRT - CPHI
24%
Poorly correlated
+0.83%
CRON - CPHI
23%
Poorly correlated
-3.28%
PAHC - CPHI
22%
Poorly correlated
-4.61%
SXTC - CPHI
22%
Poorly correlated
-16.56%
More

CRON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRON has been closely correlated with SNDL. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRON jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRON
1D Price
Change %
CRON100%
-3.28%
SNDL - CRON
73%
Closely correlated
-3.57%
TLRY - CRON
64%
Loosely correlated
-6.69%
OGI - CRON
59%
Loosely correlated
-2.58%
CGC - CRON
57%
Loosely correlated
-1.40%
ACB - CRON
56%
Loosely correlated
-2.82%
More